Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers

Author:

Deng Xiujiao123,Wang Jinghao12,Yu Shanshan4,Tan Suiyi3,Yu Tingting12,Xu Qiaxin12,Chen Nenghua12,Zhang Siqi5,Zhang Ming‐Rong6,Hu Kuan56ORCID,Xiao Zeyu27

Affiliation:

1. Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China

2. The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases Jinan University Guangzhou China

3. Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences Southern Medical University Guangzhou China

4. Department of Pharmacy Zhujiang Hospital Southern Medical University Guangzhou China

5. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

6. Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical, Science National Institutes for Quantum Science and Technology Chiba Japan

7. The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation Jinan University Guangzhou China

Abstract

AbstractAtherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well‐being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface‐modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over‐expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand‐modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.

Funder

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3